Call Us

0330 001 0048

Book Consultation

ARTICLES

Arthrosamid®’s story started two decades ago. The brainchild of the team at Contura, the product had been in human use for various indications since 2000, and a favourable safety profile had already been established.

PATIENTS GAIN ACCESS TO INNOVATIVE NEW PROCEDURE FOR TREATING KNEE OSTEOARTHRITIS AS HCA UK PARTNERS WITH CONTURA ORTHOPAEDICS

London, September 2022; Contura Orthopaedics Ltd is pleased to announce that a major hospital group has signed up to Arthrosamid, allowing clinicians to offer this novel procedure to its patients in London and across the UK.

musculoskeletal disorders in addition to sporting injuries and complaints at its state-of-the-art facility located on Tottenham Court Road in Central London. The treatment will be rolled out across other facilities across the HCA Healthcare UK group in the coming months.

Arthrosamid is a polyacrylamide hydrogel first developed by Contura International Ltd. It is a long-lasting intra-articular injection approved in Europe for the treatment of knee OA. The treatment has the potential to change the present care pathway for managing OA, which affects approximately

Legal & Medical Disclaimer

This article is written by an independent contributor and reflects their personal opinions and professional experience. It does not necessarily represent the views of amsk.co.uk. All guest submissions are published in good faith, and amsk.co.uk does not verify the accuracy of claims, the clinical content, or the legal ownership of any images or media submitted. The content is intended for general informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for consultation with a qualified healthcare professional. Readers should not rely on the information in this article to diagnose or treat any medical condition. Always seek personalised medical guidance from a licensed clinician before making health-related decisions. The responsibility for ensuring that all text, data, and images comply with copyright, privacy, and data protection laws lies solely with the article’s author amsk.co.uk takes no responsibility for third-party content and will act promptly to remove any material found to be inappropriate, inaccurate, or in breach of regulations. amsk.co.uk accept no liability for any loss, damage, or injury resulting from the use of or reliance on content published on this site. By accessing this article, you agree to these terms. If you believe this content breaches any rights or contains inaccurate information, please contact us at [email protected].

Innovative Ways to Manage Patellofemoral Pain Syndrome: From Exercise Selection to Everyday Movement Strategies

December 1, 2025 No Comments

Patellofemoral pain syndrome (PFPS), known as ‘runner’s knee,’ causes pain around the kneecap, affecting daily activities like walking and sitting. This condition often impacts young women and arises from muscle weakness, poor kneecap alignment, and overuse. Effective management includes targeted exercises—such as quadriceps strengthening and glute bridges—and lifestyle adjustments like proper sitting and sleeping postures. Early diagnosis and personalized treatment plans are essential, as some physical tests have limited sensitivity. While conservative treatments often relieve symptoms, persistent cases may require advanced interventions, including surgery. Utilizing evidence-based strategies and resources like NHS guides can help reduce PFPS discomfort and improve knee function, enabling a return to active, pain-free movement.

Read More »

The Science Behind Knee Gel Injections: How Synovial Fluid Supplements Relieve Osteoarthritis Pain

December 1, 2025 No Comments

Knee gel injections, primarily hyaluronic acid-based, offer a minimally invasive treatment for osteoarthritis-related knee pain by replenishing natural joint lubrication and cushioning. These injections mimic synovial fluid to reduce friction, inflammation, and discomfort, enhancing mobility and daily activities. Various products like Synvisc, Euflexxa, and the newer polyacrylamide hydrogel Arthrosamid differ in formulation and duration of relief, with Arthrosamid showing promising longer-lasting effects up to 12 months. The injection process is simple and typically well-tolerated, making it suitable for moderate osteoarthritis cases unresponsive to other treatments. Consulting healthcare professionals is vital to tailor therapy for optimal results. This approach addresses joint health directly, improving quality of life by targeting the underlying lubrication loss in osteoarthritic knees.

Read More »

Subscribe to our mailing list

Contact Us

Useful Link

Recent Post

Product

Arthrosamid® is a registered trademark of Contura A/S. AMSK is not affiliated with or endorsed by Contura A/S.

© 2022 AMSK All Rights Reserved | Website By Soft Minders

Facebook-f Twitter Instagram Linkedin